Amoxicillin/clavulanic acid controlled release - GlaxoSmithKline

Drug Profile

Amoxicillin/clavulanic acid controlled release - GlaxoSmithKline

Alternative Names: Amoxicillin 1000mg/clavulanic acid 62.5mg; Amoxicillin/clavulanic acid modified release; Augmentin SR; Augmentin XR; Extended-release amoxicillin/clavulanic acid; Pharmacokinetically enhanced amoxicillin/clavulanate - GSK

Latest Information Update: 22 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Beta-lactams; Penicillins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Acute sinusitis; Community-acquired pneumonia

Most Recent Events

  • 27 Jun 2005 Data presented at the 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2005) have been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 03 Nov 2003 Data presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA-2003) have been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 17 Oct 2003 Registered for Acute exacerbations of chronic bronchitis in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top